cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Gilead Sciences Inc
172 own
158 watching
Current Price
$65.06
$1.5
(2.36%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
98,108.85M
52-Week High
52-Week High
87.87000
52-Week Low
52-Week Low
62.07000
Average Volume
Average Volume
9.32M
Dividend Yield
Dividend Yield
0.04237
P/E Ratio
P/E Ratio
11.3194
iconMarket Capitalization98,108.85M
icon52-Week High87.87000
icon52-Week Low62.07000
iconAverage Volume9.32M
iconDividend Yield0.04237
iconP/E Ratio11.3194
What does the Gilead Sciences Inc do?
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Read More
How much money does Gilead Sciences Inc make?
News & Events about Gilead Sciences Inc.
TipRanks Financial Blog
11 months ago
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amneal Pharmaceuticals (AMRX Research Report), Replimune Group ... Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amneal Pharmaceuticals (AMRX Research Report), Replimune Group...
Zolmax
11 months ago
Hennion & Walsh Asset Management Inc. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD Free Report) by 7.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,569 shares of the biopharmaceutical ...
Ticker Report
11 months ago
Altfest L J Co. Inc. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD Free Report) by 7.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities Exchange Commission. The institutional investor owned 3,747 ...
Business Wire
11 months ago
Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 96 results from the pivotal MYR301 Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex (bulevirtide) for the treatment of adults with chronic hepatitis delta (HDV) infection. These new data presented at the...
Business Wire
11 months ago
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Trodelvy (sacituzumab govitecan) as monotherapy for the treatment of adult patients with unresectable or...
Frequently Asked Questions
Frequently Asked Questions
What is Gilead Sciences Inc share price today?
plus_minus_icon
Can Indians buy Gilead Sciences Inc shares?
plus_minus_icon
How can I buy Gilead Sciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Gilead Sciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Gilead Sciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Gilead Sciences Inc?
plus_minus_icon
What is today’s market capitalisation of Gilead Sciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Gilead Sciences Inc?
plus_minus_icon
What percentage is Gilead Sciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Gilead Sciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$65.06
$1.5
(2.36%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00